New FISH Test Developed for Colorectal Cancer Detection
By LabMedica International staff writers
Posted on 23 Nov 2009
New tissue-based fluorescence in situ hybridization (FISH) technology is the first test developed for the detection of chromosomal anomalies associated with colon cancer. Posted on 23 Nov 2009
"We are excited to be the first laboratory to offer GastroFISH for the colon. Using current histological techniques, identifying adenomas with a high risk for progression to cancer is not possible. Multitarget FISH will be helpful in the identification of these adenomas in conjunction with histology,” said Junqi Qian, M.D., director of molecular diagnostics at Bostwick Laboratories (Glen Allen, VA, USA).
GastroFISH, developed by Gastrocor (Glen Allen, VA, USA), is a diagnostic test with a high sensitivity and specificity that will aid in the differential diagnosis of adenoma from adenocarcinoma. The results from GastroFISH, together with a pathology diagnosis, will assist the physician in guiding a more effective treatment plan for the patient.
Related Links:
Gastrocor
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
